Gradalis Revenue and Competitors
Estimated Revenue & Valuation
- Gradalis's estimated annual revenue is currently $2.2M per year.
- Gradalis's estimated revenue per employee is $77,500
- Gradalis's total funding is $90M.
Employee Data
- Gradalis has 29 Employees.
- Gradalis grew their employee count by -12% last year.
Gradalis's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Chairman the Board | Reveal Email/Phone |
2 | Controller | Reveal Email/Phone |
3 | VP, Clinical and Regulatory Operations | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP, Medical and Scientific Affairs | Reveal Email/Phone |
6 | SVP Clinical and Regulatory Operations | Reveal Email/Phone |
7 | Chief Operating Officer | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Director - Scientific Liaison | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Gradalis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.5M | 16 | 45% | N/A | N/A |
#2 | $13.8M | 89 | -7% | N/A | N/A |
#3 | $18.6M | 120 | 3% | $1.8M | N/A |
#4 | $0.9M | 6 | -40% | N/A | N/A |
#5 | $4.2M | 27 | 0% | N/A | N/A |
#6 | $3.4M | 22 | 47% | N/A | N/A |
#7 | $9.6M | 62 | 29% | N/A | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $1.7M | 11 | 10% | N/A | N/A |
#10 | $15.2M | 98 | -8% | N/A | N/A |
What Is Gradalis?
We are a late-stage biopharmaceutical company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil®, our proprietary immunotherapy platform in multiple advanced cancer indications.
keywords:N/A$90M
Total Funding
29
Number of Employees
$2.2M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gradalis News
Achilles Therapeutics plc; Advaxis, Inc.; Frame Cancer Therapeutics; Genocea, Gradalis, Inc.; Gritstone Oncology; Immunicum AB; Medigene AG;...
... To Grow During the Forecast Period (2019-2032), DelveInsight | Key Companies- Gradalis, Eisai, Salarius Pharmaceuticals, and Others.
... Novocure, Gradalis, Karyopharm Therapeutics, Bayer, EMD Merck, Macrogenics, Sorrento Therapeutics, US Oncology, Myriad Pharmaceuticals.
Gradalis, a Dallas, Texas-basedbiotechnology company, has raised $24m in Series B financing. Backers were not disclosed. Led by David Shanahan, president, CEO and co-founder, Gradalis focuses on developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in t ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.9M | 29 | -6% | N/A |
#2 | $6.6M | 29 | 7% | N/A |
#3 | $3.6M | 30 | -9% | N/A |
#4 | $7.9M | 30 | 11% | N/A |
#5 | $7.5M | 30 | 0% | N/A |